Clicky

Oncolytics Biotech Inc.(ONCY) News

Date Title
Oct 7 ONCY Stock Up on Regulatory Update From Breast Cancer Program
Oct 7 Oncolytics targets accelerated approval for oncolytic virus therapy
Oct 4 Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
Aug 2 Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
Aug 1 Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
Jul 24 Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Jun 27 Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
Jun 27 Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Jun 24 Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Jun 21 Oncolytics doses first subject in pancreatic cancer trial
Jun 20 Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Jan 9 Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
Dec 7 Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Nov 5 Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript
Nov 3 Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Nov 3 Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Sep 8 Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
Sep 7 Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
Sep 6 Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
Jun 22 Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial